Mycophenolate Mofetil

@article{Fulton2012MycophenolateM,
  title={Mycophenolate Mofetil},
  author={Bret Fulton and Anthony Markham},
  journal={Drugs},
  year={2012},
  volume={51},
  pages={278-298}
}
SynopsisMycophenolate mofetil is an ester prodrug of the active immunosuppressant mycophenolic acid. It is a noncompetitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase, an important enzyme in the de novo synthesis of guanosine nucleotides in T and B lymphocytes. Mycophenolate mofetil and/or mycophenolic acid inhibit the proliferation of lymphocytes and the production of antibodies induced by a variety of mitogens and antigens. Mycophenolate mofetil is also active… Expand
Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells
TLDR
The data suggest that MPA can interrupt the vicious pathogenic spiral of autoimmune disorders by regulating the function of DC subsets, and unveiled a novel mechanism for the therapeutic ability of MMF against SLE. Expand
Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low‐dose tacrolimus, for renal allograft rejection in non‐human primates
TLDR
It is suggested that AS2553627 replacing MMF in combination with a sub‐therapeutic dose of TAC to treat allograft rejection in a monkey model is an attractive CNI‐sparing strategy to prevent renal allografted rejection. Expand
Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
TLDR
A systematic review and meta-analysis found no difference between the therapeutic efficacy of MMF and that of CYC in patients with AAV, suggesting that MMF may be an alternative remission induction therapy in Patients with non-life-threatening AAV. Expand
Combination of tacrolimus and mycophenolate mofetil induces oxidative stress and genotoxicity in spleen and bone marrow of Wistar rats.
TLDR
TAC/MMF associated induction in oxidative stress plays a role in the splenic and bone marrow toxicity and enhances the different endpoints of genotoxicity, suggesting its mutagenic action in vivo. Expand
Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn’s Disease Mouse Model
TLDR
Treatment with MMF may improve experimental colitis and induce inflammatory response remission of CD by down-regulation of pro-inflammatory cytokines via modulation of the differentiation of Th1/Th2 cells. Expand
Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
TLDR
Recurrence of severe skin involvement occurred in 26.3% of patients with rp-dcSSc following MMF discontinuation or dose reduction, requiring prompt MMF therapy resumption and it is suggested that MMF treatment should be maintained for longer than 2 years. Expand
Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A
TLDR
A high‐throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet dis‐ orders and the impact of Glu102Lys on the factor X function in a patient with a doubly ho‐ mozygous factor X deficiency is presented. Expand
Treatment: Immunomodulatory Drugs
TLDR
In Japan, to prevent relapses in type 1 AIP (including IgG4-SC), many patients are advised to continue daily low-dose prednisolone for months to years following induction of remission, and this maintenance of steroid therapy has its advantages and disadvantages. Expand
Long-term effects of mycophenolic acid on the immunoglobulin and inflammatory marker-gene expression in sheep white blood cells
TLDR
According to the data, oral uptake of silage extremely contaminated with a very high concentration of MPA did not have a significant influence on immunoglobulins and cytokines in WBC. Expand
HIV-associated immune activation: from bench to bedside.
TLDR
An update on the causes and consequences of the HIV-associated immune activation, and a summary of the immune modulatory approaches that are currently under clinical investigation are provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
TLDR
It is concluded that mizoribine selectively inhibits guanine ribonucleotide formation in purified T cells, whereas the effect of 6MP appears to be more dependent on adenine rib onucleotide depletion. Expand
The design and development of an immunosuppressive drug, mycophenolate mofetil
TLDR
Patients with diseases such as rheumatoid arthritis and organ transplant recipients are treated with immunosuppressive agents for years, and when such a drug is withdrawn immune function can soon recover to control the infections. Expand
Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single Center
TLDR
The results of these two studies indicate that mycophenolate mofetil could be administered safely to renal allograft recipients for periods up to 2 years, and appears to be effective in reversing acute rejection in a high percentage of patients refractory to other forms of therapy. Expand
RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection
TLDR
It is suggested that this pilot study suggests that RS-61443 is effective in refractory kidney allograft rejection and prospectively randomized multi-center trails have been planned and are in progress. Expand
RS-61443--a new, potent immunosuppressive agent.
TLDR
Long-term administration of RS-61443 (20 mg/kg/day) did not cause nephrotoxicity, hematot toxicity, or hepatotoxicity, with the exception of a slight elevation of the alkaline phosphatase levels. Expand
SUPPRESSION OF SYNTHESIS OF NATURAL ANTIBODIES BY MYCOPHENOLATE MOFETIL (RS‐61443): ITS POTENTIAL USE IN DISCORDANT XENOGRAFTING
TLDR
Use of this drug, perhaps with more conventional agents, may allow suppression of NA for a significant period after transplantation, and it has been shown that RS-61443 can be administered for longer periods. Expand
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients. Expand
Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy.
TLDR
Combined therapy significantly prolonged graft survival, and that the progression of advanced rejection was halted immediately, demonstrated that RS and DUP combination may provide a potent immunosuppressive therapy in clinical transplantation. Expand
Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
TLDR
MMF is the first demonstration that MMF significantly inhibits human B cell responses to antigen in vivo, and is associated with a reduced incidence and titer of IgG anti-ATGAM antibody formation compared with standard azathioprine dosing. Expand
Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion
TLDR
It is suggested that MPA does not inhibit early responses of T and B lymphocytes lo mitogenic or antigenic stimulation but blocks the cells at the time of DNA synthesis, the cytostatic effect of MPA is more potent on lymphocytes than on other cell types, such as fibroblasts and endothelial cells. Expand
...
1
2
3
4
5
...